

# Iain B Squire

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5402413/publications.pdf>

Version: 2024-02-01

59  
papers

6,552  
citations

159585

30  
h-index

133252

59  
g-index

60  
all docs

60  
docs citations

60  
times ranked

8118  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	27.0	2,821
2	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013, 34, 1404-1413.	2.2	921
3	Risk Related to Pre-diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	260
4	Acute Heart Failure: Definition, Classification and Epidemiology. <i>Current Heart Failure Reports</i> , 2017, 14, 385-392.	3.3	217
5	Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. <i>Journal of Cardiac Failure</i> , 2004, 10, 328-333.	1.7	151
6	Risk Factors for Nonadherence to Antihypertensive Treatment. <i>Hypertension</i> , 2017, 69, 1113-1120.	2.7	150
7	Regulatory RNAs in Heart Failure. <i>Circulation</i> , 2020, 141, 313-328.	1.6	133
8	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	2.8	118
9	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	2.2	114
10	Risk Factors for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006472.	3.9	100
11	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.1	93
12	Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. <i>European Journal of Heart Failure</i> , 2001, 3, 15-19.	7.1	85
13	20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. <i>Lancet Public Health</i> , The, 2019, 4, e406-e420.	10.0	82
14	Prognosis for South Asian and white patients newly admitted to hospital with heart failure in the United Kingdom: historical cohort study. <i>BMJ: British Medical Journal</i> , 2003, 327, 526-531.	2.3	79
15	Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of Microvascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. <i>European Heart Journal</i> , 2017, 38, 1222-1229.	2.2	72
16	Sacubitril/valsartan: beyond natriuretic peptides. <i>Heart</i> , 2017, 103, 1569-1577.	2.9	72
17	Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. <i>European Heart Journal</i> , 2011, 32, 706-711.	2.2	71
18	Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 56-69.	2.8	66

#	ARTICLE	IF	CITATIONS
19	COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. The Cochrane Library, 2022, 2022, CD013879.	2.8	66
20	Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLoS ONE, 2015, 10, e0142237.	2.5	65
21	Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction – implications for clinical trials. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 4.	3.3	62
22	Proenkephalin and Prognosis After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 280-289.	2.8	56
23	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.	2.2	53
24	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <scp>MAGGIC</scp> meta-analysis. European Journal of Heart Failure, 2015, 17, 1182-1191.	7.1	48
25	Cardiotrophin-1 protects the human myocardium from ischemic injury Comparison with the first and second window of protection by ischemic preconditioning. Cardiovascular Research, 2000, 48, 440-447.	3.8	46
26	N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clinical Science, 2004, 107, 309-316.	4.3	42
27	The rational use of $\beta$ -adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy. British Journal of Clinical Pharmacology, 2000, 49, 1-9.	2.4	40
28	Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clinical Science, 2002, 102, 9-14.	4.3	40
29	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, 2021, 144, 199-209.	1.6	40
30	Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management. European Heart Journal, 2020, 41, 2197-2205.	2.2	35
31	Patient, health service factors and variation in mortality following resuscitated out-of-hospital cardiac arrest in acute coronary syndrome: Analysis of the Myocardial Ischaemia National Audit Project. Resuscitation, 2018, 124, 49-57.	3.0	32
32	Resuscitated cardiac arrest and prognosis following myocardial infarction. Heart, 2014, 100, 1125-1132.	2.9	23
33	Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technology Assessment, 2015, 19, 1-120.	2.8	23
34	Comparison of global myocardial strain assessed by cardiovascular magnetic resonance tagging and feature tracking to infarct size at predicting remodelling following STEMI. BMC Cardiovascular Disorders, 2017, 17, 7.	1.7	22
35	Global myocardial strain assessment by different imaging modalities to predict outcomes after ST-elevation myocardial infarction: A systematic review. World Journal of Cardiology, 2015, 7, 948.	1.5	22
36	The effect of valvular regurgitation on plasma Cardiotrophin-1 in patients with normal left ventricular systolic function. European Journal of Heart Failure, 2000, 2, 387-391.	7.1	20

#	ARTICLE	IF	CITATIONS
37	Diagnostic accuracy of screening questionnaires for obstructive sleep apnoea in adults in different clinical cohorts: a systematic review and meta-analysis. <i>Sleep and Breathing</i> , 2022, 26, 1053-1078.	1.7	20
38	Distinct and complementary roles for $\hat{1}\pm$ and $\hat{1}^2$ isoenzymes of PKC in mediating vasoconstrictor responses to acutely elevated glucose. <i>British Journal of Pharmacology</i> , 2016, 173, 870-887.	5.4	19
39	Pro-Substance P for Evaluation of Risk in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1698-1707.	2.8	17
40	Prognostic Role of Molecular Forms of B-Type Natriuretic Peptide in Acute Heart Failure. <i>Clinical Chemistry</i> , 2017, 63, 880-886.	3.2	16
41	In-hospital worsening heart failure: a clinically relevant endpoint?. <i>ESC Heart Failure</i> , 2018, 5, 9-18.	3.1	16
42	Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 397-413.	2.1	15
43	Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 1133-1146.	1.5	13
44	Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study. <i>Clinical Research in Cardiology</i> , 2019, 108, 940-949.	3.3	12
45	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 296-301.	3.0	12
46	Survival in South Asian and White European patients after acute myocardial infarction. <i>Heart</i> , 2015, 101, 630-636.	2.9	10
47	Does stress perfusion imaging improve the diagnostic accuracy of late gadolinium enhanced cardiac magnetic resonance for establishing the etiology of heart failure?. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 98.	1.7	8
48	Socioeconomic status and outcomes in heart failure with reduced ejection fraction. <i>Heart</i> , 2018, 104, 966-967.	2.9	8
49	Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 67-74.	2.6	7
50	Evidence for reduced susceptibility to cardiac bradycardias in South Asians compared with Caucasians. <i>Heart</i> , 2018, 104, 1350-1355.	2.9	7
51	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. <i>Heart</i> , 2022, 108, 16-21.	2.9	7
52	Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction. <i>IJC Heart and Vasculature</i> , 2015, 9, 55-62.	1.1	5
53	A novel form of glycolytic metabolism-dependent cardioprotection revealed by PKC $\hat{1}\pm$ and $\hat{1}^2$ inhibition. <i>Journal of Physiology</i> , 2019, 597, 4481-4501.	2.9	5
54	Biomarkers and prognostication in heart failure with reduced and preserved ejection fraction: similar but different?. <i>European Journal of Heart Failure</i> , 2017, 19, 1648-1650.	7.1	4

#	ARTICLE	IF	CITATIONS
55	Variation in outcome of hospitalised patients with out-of-hospital cardiac arrest from acute coronary syndrome: a cohort study. <i>Health Services and Delivery Research</i> , 2018, 6, 1-116.	1.4	3
56	Developing a core outcome set for patient-reported symptom monitoring to reduce hospital admissions for patients with heart failure. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 830-839.	0.9	3
57	T-cell recognition of discrete regions of the thrombolytic drug streptokinase. <i>Clinical Science</i> , 2000, 99, 239-246.	4.3	2
58	Growth hormone for risk stratification and effects of therapy in acute myocardial infarction. <i>Biomarkers</i> , 2015, 20, 371-375.	1.9	2
59	British Society of Heart Failure. <i>European Heart Journal</i> , 2018, 39, 2773-2774.	2.2	1